BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 12511176)

  • 1. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study.
    Kiefer F; Jahn H; Tarnaske T; Helwig H; Briken P; Holzbach R; Kämpf P; Stracke R; Baehr M; Naber D; Wiedemann K
    Arch Gen Psychiatry; 2003 Jan; 60(1):92-9. PubMed ID: 12511176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
    Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
    Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy].
    Gahr M; Kölle MA; Schönfeldt-Lecuona C
    Nervenarzt; 2013 May; 84(5):584-9. PubMed ID: 22892944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
    Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
    Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.
    Morley KC; Teesson M; Reid SC; Sannibale C; Thomson C; Phung N; Weltman M; Bell JR; Richardson K; Haber PS
    Addiction; 2006 Oct; 101(10):1451-62. PubMed ID: 16968347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome.
    Kiefer F; Helwig H; Tarnaske T; Otte C; Jahn H; Wiedemann K
    Eur Addict Res; 2005; 11(2):83-91. PubMed ID: 15785069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
    Soyka M; Preuss U; Schuetz C
    Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.
    Donovan DM; Anton RF; Miller WR; Longabaugh R; Hosking JD; Youngblood M;
    J Stud Alcohol Drugs; 2008 Jan; 69(1):5-13. PubMed ID: 18080059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence.
    Kiefer F; Andersohn F; Otte C; Wolf K; Jahn H; Wiedemann K
    Acta Neuropsychiatr; 2004 Oct; 16(5):233-8. PubMed ID: 26984435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
    Kranzler HR; Van Kirk J
    Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined therapy: what does acamprosate and naltrexone combination tell us?
    Kiefer F; Wiedemann K
    Alcohol Alcohol; 2004; 39(6):542-7. PubMed ID: 15456690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism.
    Kiefer F; Jahn H; Otte C; Demiralay C; Wolf K; Wiedemann K
    J Psychiatr Res; 2005 Sep; 39(5):545-51. PubMed ID: 15992564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment.
    Mason BJ
    Eur Neuropsychopharmacol; 2003 Dec; 13(6):469-75. PubMed ID: 14636963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
    Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
    Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
    Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for combining acamprosate and naltrexone for treating alcohol dependence.
    Mason BJ
    J Stud Alcohol Suppl; 2005 Jul; (15):148-56; discussion 140. PubMed ID: 16223066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects.
    Johnson BA; O'Malley SS; Ciraulo DA; Roache JD; Chambers RA; Sarid-Segal O; Couper D
    J Clin Psychopharmacol; 2003 Jun; 23(3):281-93. PubMed ID: 12826990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Bouza C; Angeles M; Muñoz A; Amate JM
    Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence.
    Sass H; Soyka M; Mann K; Zieglgänsberger W
    Arch Gen Psychiatry; 1996 Aug; 53(8):673-80. PubMed ID: 8694680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.